Switzerland first, or Germany first? Sequencing a DACH launch

Almost every partner arriving with a DACH plan opens the same way: Germany first, because Germany is biggest. Market size is a reasonable tiebreaker and a poor first criterion. Three other factors decide the better order more often.

Switzerland is a separate jurisdiction

Switzerland is not an EU member and does not apply EU pharmaceutical law. It runs its own authorisation process through Swissmedic, its own view on borderline products, and its own labelling requirements. A dossier assembled for Germany does not transfer unchanged, and a Swiss authorisation does not open an EU door.

Liechtenstein is the useful asymmetry here: it is inside the EEA for pharmaceutical purposes while sitting in a customs and currency union with Switzerland. That is why our own quality scope in Vaduz and our distribution branch in Trogen serve different regulatory purposes rather than duplicating each other.

Treating Switzerland as “Germany, but smaller” is the most common and most expensive planning error in a DACH entry.

Regulatory route beats market size

If the product’s classification is settled and defensible, Germany’s scale argues for going first. If the classification is borderline — a botanical near a dose threshold, or a claim set that has not been through a legal review — Germany is the worst place to discover it.

The German market has an active competitive-law enforcement culture. Competitors and consumer associations can and do challenge marketing claims directly, without waiting for an authority. A claim framework that has never been stress-tested will be tested there, quickly, and a challenge can force pack and web copy to be rebuilt mid-launch.

Where the regulatory position is uncertain, a smaller first market is not caution — it is cheaper information.

Pricing reference effects

Pharmacy pricing is visible across borders. Online pharmacies serving German consumers are routinely compared against Austrian listings, and Swiss consumers compare across the border in both directions. The price you set in the first market becomes the reference for the next two, and correcting it downward later is far easier than correcting upward.

Sequence so that your highest-price market goes first, or at least so that the first market does not set a reference you cannot live with. This single consideration reverses more launch plans than any regulatory argument.

Channel structure differs more than the language suggests

Austria’s wholesale concentration cuts both ways: fewer conversations to have, but less room to recover from a rejected listing. In practice, Austria is most efficient as a confirmation step after a German listing exists, because the commercial case is already assembled in the terms Austrian buyers use.

A defensible default

For a product with a clean classification and a price point that can carry Switzerland: Switzerland, then Germany, then Austria. The Swiss launch validates the pack and the claim set in a smaller, higher-price market; Germany then carries volume without setting the price floor; Austria follows on an assembled case.

For a product with an uncertain classification or a thin margin: Germany first, deliberately slowly — resolve the regulatory route before spend scales, and treat the first six months as a claim-framework test rather than a volume ramp.

Neither order is universally right. What is universally wrong is choosing by market size alone.

We sequence markets as part of market access, after the classification assessment rather than before it.